Get the Stockscreener App
27.79
1.02%
0.28
After Hours:
26.90
-0.89
-3.20%
Uniqure N V stock is traded at $27.79, with a volume of 3.99M.
It is up +1.02% in the last 24 hours and down -52.02% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$27.51
Open:
$26.12
24h Volume:
3.99M
Relative Volume:
1.00
Market Cap:
$1.52B
Revenue:
$14.34M
Net Income/Loss:
$-199.00M
P/E Ratio:
-7.0893
EPS:
-3.92
Net Cash Flow:
$-183.51M
1W Performance:
-58.95%
1M Performance:
-52.02%
6M Performance:
+176.24%
1Y Performance:
+274.02%
1-Day Range:
$25.62
$28.39
1-Week Range:
$22.85
$36.19
52-Week Range:
$5.50
$71.50
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
27.79 | 1.69B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
NASDAQ: QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
What data driven models say about uniQure N.V.’s futureMarket Volume Report & Long Hold Capital Preservation Tips - newser.com
Predicting uniQure N.V. trend using moving averages2025 Technical Patterns & Entry and Exit Point Strategies - newser.com
uniQure NV Hits Day Low of $26.25 Amid Price Pressure - Markets Mojo
NASDAQ: QURE Investigation Reminder: Kessler Topaz Meltzer - GlobeNewswire
NASDAQ: QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
Uniqure NV expected to post a loss of 90 cents a shareEarnings Preview - TradingView
Volatility clustering patterns for uniQure N.V.Entry Point & Short-Term Trading Opportunity Alerts - newser.com
Can uniQure N.V. (UQ1) stock sustain revenue momentumJuly 2025 Patterns & Fast Moving Trade Plans - newser.com
UniQure’s FDA Nightmare: How A Single Therapy Sparked A $300M Meltdown! - Smartkarma
Is uniQure N.V. stock trading at a premium valuation2025 Key Lessons & Daily Technical Forecast Reports - newser.com
uniQure to Announce Third Quarter 2025 Financial Results - The Manila Times
uniQure Stock Tumbled 55% Today: What’s The FDA Angle? - MSN
uniQure (NASDAQ: QURE) to Host Earnings Call Nov. 10 at 8:30 a.m. ET, before market open - Stock Titan
The FDA is a mess, but don’t blame it for everything - statnews.com
uniQure N.V. stock outlook for YEARMarket Performance Report & Expert Approved Momentum Trade Ideas - newser.com
What catalysts could drive uniQure N.V. stock higherPortfolio Risk Report & Intraday High Probability Alerts - newser.com
Risk adjusted return profile for uniQure N.V. analyzedJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Can uniQure N.V. stock hit record highs againJuly 2025 Institutional & Fast Entry and Exit Trade Plans - newser.com
How institutional buying supports uniQure N.V. stockMarket Activity Recap & Entry Point Confirmation Signals - newser.com
Can uniQure N.V. stock hit analyst price targets2025 Biggest Moves & Verified Entry Point Detection - newser.com
Has uniQure’s Volatile 63% Drop Created a Compelling Opportunity After Pipeline News? - simplywall.st
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection - Benzinga
UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V. on Behalf of ... - Bluefield Daily Telegraph
UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
uniQure (NASDAQ:QURE) Trading Down 14.7% Following Analyst Downgrade - MarketBeat
uniQure NV Hits Day Low of $22.85 Amid Price Pressure - Markets Mojo
Y Intercept Hong Kong Ltd Purchases New Stake in uniQure N.V. $QURE - MarketBeat
uniQure (QURE): Examining Valuation Following Recent Share Price Volatility - simplywall.st
Goldman Sachs Maintains uniQure N.V. (QURE) Neutral Recommendation - Nasdaq
Traders Purchase Large Volume of uniQure Call Options (NASDAQ:QURE) - MarketBeat
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential ... - Enidnews.com
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces - GlobeNewswire
QURE ALERT: UniQure Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact The Firm - ACCESS Newswire
UniQure Is Latest Gene Therapy Sponsor Surprised By US FDA Reversal - Citeline News & Insights
Chardan Capital Has Lowered Expectations for uniQure (NASDAQ:QURE) Stock Price - MarketBeat
Top Small Cap Stocks To Follow TodayNovember 3rd - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Stockholders to Connect - ACCESS Newswire
uniQure N.V. Securities Lawsuit Investigation - Claim Depot
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy - Benzinga
uniQure (QURE) Sees Analyst Price Target Lowered by RBC Capital - GuruFocus
uniQure (NASDAQ:QURE) Shares Gap DownHere's Why - MarketBeat
uniQure (QURE) Analyst Rating Update: Goldman Sachs Lowers Price Target | QURE Stock News - GuruFocus
uniQure (QURE) Shares Drop Over 15% Amid Market Shifts - GuruFocus
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Cuts Target Price to $38 - 富途牛牛
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Business Wire
UniQure: Controversy Abounds As Stock Price Halves On FDA News (NASDAQ:QURE) - Seeking Alpha
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $70 - 富途牛牛
Chardan Cuts Price Target on uniQure to $53 From $76, Keeps Buy Rating - MarketScreener
RBC Cuts Price Target on uniQure to $45 From $65, Keeps Outperform, Speculative Risk - MarketScreener
William Blair Downgrades uniQure N.V to Market Perform From Outperform - MarketScreener
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kaye Jack | Director |
Nov 04 '25 |
Sale |
30.34 |
38,810 |
1,177,517 |
20,439 |
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):